Home » PROMETIC BEGINS PATIENT ENROLLMENT FOR STUDY OF PBI-1402
PROMETIC BEGINS PATIENT ENROLLMENT FOR STUDY OF PBI-1402
ProMetic BioSciences has begun the enrollment of patients for its Phase Ib/II clinical trial of PBI-1402. The study is designed to monitor the safety and efficacy of its compound in cancer patients undergoing chemotherapy and suffering from anemia.
Several experiments demonstrated the effect of PBI-1402 in mice that had their immune system suppressed by chemotherapy. The results demonstrated that PBI-1402 promotes the growth of red blood cells, and also protects various tissues such as spleen and bone marrow from the toxic effects of chemotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May